Abstract
The clinical implications of pharmacogenetics are vast and many more are becoming apparent as research continues. Health-care providers will increasingly need to take pharmacogenetics into consideration when prescribing medications. Each patient’s history, physical condition, gender, and ethnicity must be considered when prescribing drugs. Specific genotypic testing of patients for polymorphisms that influence drug metabolism and action will become a clinical reality. Silicone chip technology utilizing single-nucleotide polymorphisms will be able to provide a practitioner with reliable and timely information in an office setting to guide practice. Genetics and pharmacology are no longer separate sciences.
Key Words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Selected References
Carson PE, Flanagan CL, Ickes CE, Alvong AS. Enzymatic deficiency in primaquine sensitive erythrocytes. Science 1956;124:484, 485.
Committee on Quality of Health Care in America: Institute of Medicine. To Err is Human: Building A Safer Health System. Washington, DC: National Academy Press, 2000.
Evans DA. Genetic variations in the acetylation of isoniazid and other drugs. Ann N Y Acad Sci 1968;151(2):723–733.
Flockhart DA. Drug Interactions: Defining genetic influences on pharma-cologic responses. Indiana University School of Medicine, Division of Clinical Pharmacology. Indianapolis, Indiana. http://www.drug-interactions.com. Retrieved January 20, 2004.
Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: Do recent market removals mean there is a problem? JAMA 1999;281(18): 1728–1734.
Garrod AE, Harris H. Garrod’s Inborn Errors of Metabolism. London, New York: Oxford University Press, 1963.
Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109(2):87–94.
Guthrie R. Screening for “inborn errors of metabolism” in the newborn infant-a multiple test program. Birth Defects 1968;4:92–98.
Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001;250(3): 186–200.
Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20(8):342–349.
Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycopro-tein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101(2):289–294.
Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med, 1998; 338(2): 86–93.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279(15):1200–1205.
Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999;56(4):247–258.
Smith RL. The paton prize award. The discovery of the debrisoquine hydroxylation polymorphism: scientific and clinical impact and consequences. Toxicology 2001;168(1):11–19.
Trenter M. From test tube to patient: improving health through human drugs. Washington, D C: U.S. Food and Drug Administration Center for Drug Evaluation and Research, 1999 pp. 1–100.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this chapter
Cite this chapter
Edkins, R.E., Cheek, D.J. (2006). Pharmacogenetics. In: Runge, M.S., Patterson, C. (eds) Principles of Molecular Medicine. Humana Press. https://doi.org/10.1007/978-1-59259-963-9_5
Download citation
DOI: https://doi.org/10.1007/978-1-59259-963-9_5
Publisher Name: Humana Press
Print ISBN: 978-1-58829-202-5
Online ISBN: 978-1-59259-963-9
eBook Packages: MedicineMedicine (R0)